Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

    NEXT STORY
    Influenza Diagnostic Tests Market to hit $1.5 billion by 2025: Global Market Insights, Inc.
    PREV STORY
    Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass. and BEIJING, China, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News

    Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

    author_avatar
    NASDAQ Market News

    Cesca Therapeutics Inc. Announces Two Abstracts Accepted for Poster Presentation at the International Society for Cellular Therapy (ISCT) 2018 Annual Meeting

    RANCHO CORDOVA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) ...

    author_avatar
    NASDAQ Market News